Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...
4don MSN
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.
Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...
Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results